Hoth Therapeutics Inc HOTH shares are trading higher by 17% to $0.47 Tuesday morning after the company announced its HT-ALZ therapeutic showed cognitive improvements in an Alzheimer's Disease (AD) mouse model.
Hoth Therapeutics says all of the behavioral tests performed after >5 weeks treatment showed a significant improvement in the HT-ALZ treated groups compared to the vehicle treated groups, with similar cognitive and behavioral trends in the HT-ALZ-treated groups compared to the wild type (non-AD) animals. Overall, Hoth Therapeutics says the results support the therapeutic potential of HT-ALZ to provide cognitive improvement as an AD therapeutic.
AD is a neurodegenerative disease that is characterized by aggregates of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, which contribute to the clinical symptoms of the disease such as dementia.
See Also: Why Canoo Shares Shot Up Over 100% Today
Hoth Therapeutics is a development-stage biopharmaceutical company.
According to data from Benzinga Pro, Hoth Therapeutics has a 52-week high of $1.75 and a 52-week low of $0.38.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
